Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

Follicular lymphoma is the most common, slow-growth type of non-Hodgkin lymphoma (NHL) – a form of blood cancer – which often returns after a first therapy. ... The FDA is expected to decide on the approval of the novel cancer immunotherapy by 29

Latest news

More from news
Approximately 10 fully matching, plus 257 partially matching documents found.

Latest Intelligence

  • Patient diversity in clinical trials needs to be centre stage Patient diversity in clinical trials needs to be centre stage

    For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... BMS will become the fourth largest pharma firm by sales – behind Pfizer, Novartis and Roche – and the addition of

  • Cell and gene therapy Cell and gene therapy

    patient.”. Althoff cites Novartis’ Kymriah (tisagenlecleucel), a blood cancer cell therapy approved in Europe and the US last year, as an example of the differing manufacturing costs.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...